Related Experiment Video
Updated: Jul 8, 2025
09:33
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
Immunotherapies for Alzheimer's disease
1Department of Pharmacology and Chemical Biology, Department of Neurology, Center for Neurodegenerative Disease, Goizueta Institute Emory Brain Health, Emory University School of Medicine, Atlanta, GA, USA.
Science (New York, N.Y.)
|December 14, 2023
Summary
New antibody treatments targeting amyloid-beta plaques show promise in slowing cognitive decline for Alzheimer's disease patients. These findings offer hope for future therapeutic strategies.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Alzheimer's disease is characterized by the accumulation of amyloid-beta (Aβ) aggregates in the brain.
- These aggregates are thought to contribute to neurodegeneration and cognitive decline.
- Current therapeutic strategies aim to clear or prevent the formation of these toxic Aβ species.
Purpose of the Study:
- To evaluate the efficacy of novel antibodies designed to target and neutralize amyloid-beta aggregates.
- To assess the impact of these antibody treatments on the rate of cognitive decline in individuals with Alzheimer's disease.
Main Methods:
- Clinical trials involving patients with early to moderate Alzheimer's disease.
- Administration of specific antibodies targeting various forms of amyloid-beta aggregates.
- Longitudinal assessment of cognitive function using standardized neurological tests.
Main Results:
- Antibody treatment groups demonstrated a statistically significant slowing of cognitive decline compared to placebo groups.
- Reduction in amyloid-beta plaque burden was observed in treated individuals.
- A correlation between target engagement and clinical benefit was noted.
Conclusions:
- Antibodies targeting amyloid-beta aggregates represent a promising therapeutic approach for Alzheimer's disease.
- Slowing cognitive decline is achievable through modulation of amyloid-beta pathology.
- Further research and long-term studies are warranted to confirm safety and efficacy.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128
01:30Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115